□ 本报记者 许雯斐 通讯员 曹昊晨 眼下，永丰路与友谊路交叉口，工程车辆穿梭，机械轰鸣作业，一片热火朝天的景象。这里是联东U谷 数智产业园项目现场，与在建中的南京北站近在咫尺。项目自去年12月开工以来，招商去化已基本完 成。地处北站"第二圈层"的黄金地段，未来，企业家、科学家出站10分钟，即可到达这里，投入高效研 发与生产工作中。 去年3月，江北新区发布《扬子江产业科技创新试验区建设方案》，在"一港、一园、四基地、八街 区"总体布局中，南京北站枢纽经济区被赋予"产业科技创新枢纽港"建设使命，成为建设蓝图中的关 键"一港"。 如今，一边是南京北站主体结构全面转入地上施工，"超级枢纽"拔节生长；另一边，是枢纽经济区内的 产业项目快马加鞭，同步推进。这片热土上，勾勒出的不仅是交通枢纽的钢铁骨架，更是一座驱动未来 的产业创新高地。 "当日拿地、次日动工"的非凡速度 "我们在全国布局众多项目，'拿地即开工'并非首次，但像这样当天拿到五张证、次日就能进场施工 的，实属首次。"近日，联东U谷项目负责人专程向江北新区数据局、建设与交通局及枢纽办等相关部 门送上锦旗，表达谢意与赞誉，"江北新区的服务效率，堪称'非凡速度'！" ...

Focus Review - The hard technology sector sees robotics becoming the hottest field, with LimX Dynamics completing a $200 million Series B financing round involving multiple renowned domestic and international investors, including Stone Venture, Dongfang Fuhai, and others [4][7] - The health sector is significantly influenced by state-owned enterprises, as Guokai Ion Medical Technology announced an 800 million yuan equity financing round led by the Zhongguancun Social Security Fund [4][24] - In the internet sector, cybersecurity is gaining traction, with ZAST.AI completing a multi-million dollar Pre-A financing round led by GL Ventures [5][34] Hard Technology Sector - LimX Dynamics completed a $200 million Series B financing round with participation from various well-known investors, including Stone Venture and JD.com [4][7] - The Beijing Humanoid Robot Innovation Center secured over 700 million yuan in market-oriented financing, attracting investments from several prominent institutions [4][12] Health Sector - Guokai Ion Medical Technology raised 800 million yuan in its first equity financing round, led by the Zhongguancun Social Security Fund [4][24] - Huaguan Biotechnology announced a multi-billion yuan Series C financing round, with investments from SoftBank and other institutions [4][26] Internet Sector - ZAST.AI, focused on vulnerability detection, completed a multi-million dollar Pre-A financing round led by GL Ventures [5][34] - Zhongzhiwei Technology announced a tens of millions B2 financing round, exclusively funded by Nanjing Yangzi Shenghong Venture Capital [5][35]

当华检医疗（01931）的股价在低迷中徘徊，一则看似平常的人事任命公告，正成为扭转战局的关键落子。 图片来源：华检医疗2月6日公告 在华检医疗股价持续承压、投资者信心亟待提振的当下，易笑的加盟绝非简单的"技术吉祥物"。其背后，是华检 医疗正试图以中国庞大的医疗市场生态为"筹码"，重构全球AI医疗技术价值分配格局的宏大叙事。 本文将深度解读，这位手握Science Advances顶刊论文、自主研发再生医学"基石材料"EBN的青年科学家，如何与 华检医疗的三大曲线战略协同，成为公司从"资本并购"迈向"生态引力"时代的核心引擎。 一、 破解估值困局：华检医疗的"反向NewCo"为何是颠覆性创新？ 智通财经APP获悉，2月6日晚间，华检医疗宣布，年仅32岁的顶尖科学家易笑博士获委任为公司执行董事兼首席 科学家。 面对全球顶尖AI医疗资产估值高企、跨境数据合规壁垒森严的时代性挑战，华检医疗没有选择重资本并购的"红 海"路径，而是开创性地推出了"反向NewCo"全球合作范式。这一模式的精髓在于 "以生态入股权，替代资本所有 权"。 具体而言，华检医疗不会直接斥巨资收购海外技术公司，而是与拥有经全球验证的尖端AI技术或产 ...

Group 1 - The company, Siyu MedTech, is a professional content and research team focused on the medical technology industry [2][3] - The team is looking for a young operational talent who can create content and drive projects to fruition [3][4] - The role involves comprehensive operations including industry events, video production, and content projects [4][6] Group 2 - The position requires interaction with medical device companies, clinical doctors, and investors [5] - Responsibilities include preparing industry events, coordinating with doctors and guests, and supporting on-site execution [6][19] - The ideal candidate should have a background in relevant fields such as medicine, pharmacy, biomedical engineering, or related areas, and possess content and video skills [12][19] Group 3 - The role offers opportunities to engage with industry experts and understand the transition of technology to clinical applications [19] - The company provides competitive compensation, social insurance, and flexible vacation policies [20] - Candidates are encouraged to submit their resumes along with links to their video work [21][22]

本报讯 （成都日报锦观新闻记者 吴怡霏） 记者2月7日获悉，成都高新区与四川大学华西第二医院（以 下简称"华西二院"）、北京银河通用机器人股份有限公司（以下简称"银河通用"）日前正式签署战略合 作协议，秉持"AI机器人中试、创新赋能医疗健康"理念，共同启动"打造具身智能机器人+健康医疗场景 创新服务共建体"合作项目，包括共建具身智能医疗机器人中试平台、打造四川首个健康医疗具身智能 场景应用示范区。 根据协议，三方将共同建设具身智能医疗机器人中试平台，共同争创国家级制造业中试平台。该中试平 台将聚焦开发"AI+健康医疗"具身智能应用系列概念样机，对具身智能机器人等产品开展训练开发，从 而为医院提供具身智能医疗机器人系列产品及解决方案，同时将构建"中试+"生态，重点开展"中试+孵 化"，孵化具身智能机器人和配套软件企业，助力企业行业总部、制造基地落户成都高新区；并与成都 高新区天使母基金等合作开展"中试+基金"，重点投向中试平台孵化企业。 此外，此次合作将依托成都高新区区域内医院和华西二院的医疗场景资源，华西二院旗下华西数字医疗 科技的数字医生解决方案，银河通用的具身智能先进技术，打造四川首个健康医疗具身智能场景 ...

Core Viewpoint - The regulatory environment in the capital market is tightening, with a "zero tolerance" approach being established, leading to an increase in investigations and administrative penalties against listed companies [6][15][22]. Group 1: Investigations and Penalties - Two companies, Aihuilong and Tiansheng New Materials, have been initiated for investigation by the China Securities Regulatory Commission (CSRC) for misleading statements and information disclosure violations, respectively [2][3][9]. - ST Funeng has received an administrative penalty due to financial fraud by its subsidiary, which inflated profits by approximately 35.8 million yuan in 2020 [3][18]. - As of February 6, 2026, a total of 11 companies have received administrative penalties this year, indicating a rapid increase in regulatory actions [5][21]. Group 2: Specific Cases - Aihuilong's investigation stems from a strategic cooperation framework agreement that was found to contain misleading statements regarding its partner, Brain Machine Star Chain [2][12]. - Tiansheng New Materials is under investigation for unspecified information disclosure violations, a common reason for CSRC investigations [9][11]. - ST Funeng's financial misconduct involved fabricating a non-existent procurement transaction, which significantly distorted its financial statements [17][18]. Group 3: Regulatory Trends - The average time for a company to be investigated after a problematic announcement has decreased, with an average of one company being investigated every five days [4][14]. - The CSRC is focusing on various types of violations, including misleading statements, market manipulation, and information disclosure violations, indicating a more granular approach to regulation [15][22]. - The regulatory response speed is increasing, reflecting a systematic effort to reshape the market ecosystem [22].

Core Viewpoint - The article emphasizes the unique position of the company, SiYu MedTech, as a professional team deeply engaged in the medical technology industry, focusing on producing in-depth content and industry research rather than traditional promotional activities [1]. Group 1: Company Overview - SiYu MedTech was established at the end of 2016 and has been operating for nearly nine years, with aspirations to recruit fresh graduates to join the rapidly evolving medical technology field by 2026 [2]. - The company serves professionals in the medical technology industry, producing specialized content that intersects clinical, technological, and industrial domains [3]. Group 2: Job Responsibilities - The role involves producing in-depth content related to various medical technology sectors, including surgical robotics, ophthalmology, cardiovascular, neurology, orthopedics, medical imaging, and aesthetic technology [3]. - Responsibilities include writing industry white papers, research reports, and systematic column planning, as well as providing content planning and communication support for medical device companies [3][4]. - The company focuses on translating technical language into industry-understandable terms and organizing industry conferences and closed-door discussions [4]. Group 3: Candidate Expectations - The company seeks candidates with a background in fields such as medicine, pharmacy, biomedical engineering, and related disciplines, with a preference for clinical or engineering backgrounds [8]. - Ideal candidates should be able to read and understand English literature, possess strong research skills, and be willing to engage with complex topics and iterative revisions [8]. Group 4: Work Environment and Benefits - The work environment allows for remote working, reducing commuting time and enabling focus on reading, thinking, and writing [13]. - The company offers flexible vacation arrangements, a stable work environment with no history of layoffs, and the opportunity for employees to engage in higher-difficulty projects as their skills grow [13].

1月6日收盘后，亚辉龙披露《关于自愿披露签署战略合作框架协议的公告》称，公司与脑机星链签订 《战略合作框架协议》，双方将在产品研发、市场推广以及股权投资等方面开展合作。 亚辉龙公告称，脑机星链是一家以人工智能为核心驱动力，深耕非侵入式与侵入式双技术路径的企业， 已开发脑电采集分析仪等产品。 涉嫌信息披露违法违规 两家公司被立案调查 ◎记者 王墨璞嘉 张问之 2月6日，亚辉龙、天晟新材因涉嫌信息披露违法违规，被中国证监会立案。其中：亚辉龙因披露签署战 略合作框架协议的公告，涉嫌误导性陈述，被证监会立案；天晟新材则可能涉及2023年度关联交易未披 露事项。 亚辉龙：披露战略合作框架协议涉嫌误导性陈述 2月6日晚间，亚辉龙公告称，收到证监会下发的《立案告知书》，因涉嫌信息披露违法违规，证监会决 定对公司立案调查。 证监会官网显示，亚辉龙披露签署战略合作框架协议的公告，涉嫌误导性陈述。近日，证监会已对亚辉 龙立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 回顾来看，亚辉龙近期发布的公告中，提及与"脑机接口"等热点概念相关的信息，但存在信息披露不准 确、不完整，风险提示不充分等问题。 亚辉龙披露 ...

Group 1 - The core viewpoint of the article highlights the aggressive share buyback strategy of Yidu Tech (医渡科技), which has repurchased approximately 1.6 million shares at around HKD 5.63 per share, totaling over HKD 9 million, marking the tenth consecutive trading day of buybacks, with a cumulative amount of about HKD 53 million [1] - The company's recent buyback activities demonstrate a "high frequency + high level" characteristic, indicating strong confidence from management in the company's intrinsic value and a clear intention to maintain market capitalization [1] - Citigroup has maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11, anticipating a potential upside of over 96% for the stock price, citing the company's unique advantages in data quality and authority derived from partnerships with top hospitals [1] Group 2 - The business segment targeting government and hospitals shows more predictable profitability compared to consumer applications, benefiting directly from increased AI budgets in hospitals and national project tenders [2] - Based on a solid business model and clear growth trajectory, Citigroup has revised its financial forecasts for the company, projecting a 17% and 30% year-on-year growth in big data platform revenue for fiscal years 2026 and 2027, respectively, with a potential to reach breakeven in fiscal year 2026 [2]

Group 1 - The core viewpoint of the news is that Yidu Tech (02158) has been actively repurchasing its shares, demonstrating confidence in its intrinsic value and a clear intention to maintain its market capitalization [1] - On February 6, the company repurchased approximately 1.6 million shares at around HKD 5.63 per share, with a total expenditure exceeding HKD 9 million, marking the tenth consecutive trading day of intensive buybacks [1] - Cumulatively, the total amount spent on share repurchases has reached approximately HKD 53 million, indicating a consistent and robust buyback strategy [1] Group 2 - Citigroup has maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11, anticipating a potential upside of over 96% for the stock price [1] - The company is recognized for its unique advantage in data quality and authority, stemming from its collaboration with top hospitals, which is crucial for the accuracy of medical AI models [1] - The business segment targeting government and hospitals shows more predictable profitability compared to consumer applications, benefiting directly from increased AI budgets in hospitals and national project tenders [2] Group 3 - Citigroup has revised its financial forecasts for Yidu Tech, projecting a 17% and 30% year-on-year growth in revenue from its big data platform for the fiscal years 2026 and 2027, respectively [2] - The company is expected to reach breakeven in the fiscal year 2026, reflecting a solid business model and clear growth trajectory [2]